ACAD Q3 2021 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$132M+9.2% YoY

Gross Profit

$125M94.9% margin

Operating Income

-$15M-11.6% margin

Net Income

-$14M-11.0% margin

EPS (Diluted)

$-0.09

QoQ Revenue Growth

+14.2%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$718M

Total Liabilities

$151M

Stockholders' Equity

$567M

Cash & Equivalents

$95M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$132M	$121M	+9.2%
Gross Profit	$125M	$116M	+7.9%
Operating Income	-$15M	-$86M	+82.2%
Net Income	-$14M	-$85M	+82.9%